LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $67.8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $7K to $105K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $67.8M and bought $0 of JNJ stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Duato, Joaquin (CEO and Chairman of the Board), who sold $44.7M. The latest filing was on Sep 4, 2026.
Rep. Lloyd Doggett (D) bought $1K to $15K on Sep 8, 2026, disclosed 27 days later. Rep. Thomas H. Kean Jr sold $1K to $15K on Aug 27, 2026, disclosed 16 days later. Sen. John Boozman (R) sold $1K to $15K on Aug 20, 2026, disclosed 22 days later. Rep. Richard Dean McCormick (R) sold $1K to $15K on Jul 30, 2026, disclosed 15 days later. In total, 4 members disclosed 7 JNJ trades with trade dates in the last 180 days, filed a median 22 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Qube Research
$191.1M
bought
Squarepoint
$138.5M
added
Millennium
$96.9M
added
Buys (1)
Sells (2)
No tracked top-trader positions in JNJ right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Oct 13, 2026
Financial period
Q3 2026
Adjusted EPS
$2.52 expected
Revenue
$25.38B expected
FY2026 guidance
$101.00B to $101.40B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Sep 30, 2026 | Oct 13, 2026 | $2.59 / $2.52Yahoo Finance | +2.69% beat | $25.40B / $25.38B | +0.07% beat |
| Jun 30, 2026 | Jul 15, 2026 | $2.90 / $2.85Yahoo Finance | +1.58% beat | $25.31B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 14, 2026 | $2.70 / $2.68Yahoo Finance | +0.85% in line | Unavailable | Unavailable |
| Dec 31, 2025 | Jan 21, 2026 | $2.46 / $2.46Yahoo Finance | -0.11% in line | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 14, 2025 | $2.80 / $2.76Alpha Vantage | +1.45% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 16, 2025 | $2.77 / $2.68Alpha Vantage | +3.36% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 15, 2025 | $2.77 / $2.58Alpha Vantage | +7.36% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 22, 2025 | $2.04 / $2.01Alpha Vantage | +1.49% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$2.88 to $3.03
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Cost of what it sold | $7.30B | $7.97B | $8.11B | $8.05B |
| Gross profit | $16.69B | $16.60B | $15.96B | $17.26B |
| What it spent | ||||
| Research and development | $3.67B | $4.25B | $3.53B | $3.65B |
| Sales and admin | $5.92B | $6.95B | $6.03B | $6.43B |
| Other operating costs | — | -$200.0M | — | — |
| Total operating expenses | $9.59B | $11.01B | $9.56B | $10.09B |
| What was left | ||||
| Operating profit | $7.10B | $5.59B | $6.39B | $7.17B |
| Interest on debt | $245.0M | $214.0M | $272.0M | $281.0M |
| Profit before tax | $7.49B | $4.97B | $5.99B | $6.75B |
| Tax | $2.34B | -$150.0M | $755.0M | $1.21B |
| Net profit | $5.15B | $5.12B | $5.24B | $5.53B |
| EBITDA | $9.29B | $7.19B | $8.27B | $8.99B |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Pfizer Inc Stock (PFE) Moved Up by 3.14% on Oct 14: Drivers Behind the Movement
NeutralOct 14Gilead Sciences Inc Stock (GILD) Moved Up by 3.12% on Oct 14: Facts Behind the Movement
NeutralOct 14AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis
Leans bullishOct 14AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis
Leans bullishOct 14Intuitive Surgical (ISRG) Stock May Be Near Fair Value Despite Fresh Robotics Competition
NeutralOct 14Tenaya Therapeutics Inc. Advanced Charts | TNYA
NeutralOct 14Quest Diagnostics Incorporated (DGX) Stock Forecasts
NeutralOct 14AT&T Inc. (T) Stock Forecasts
NeutralOct 1430 macro signals shaping JNJ right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results